

QIBA Dynamic Susceptibility Contrast (DSC-MRI) Biomarker Committee (BC) Meeting

Wednesday, January 12, 2022, at 11 a.m. (CT)

Meeting Summary

Participants

Mark Shiroishi, MD (Co-chair)

Ona Wu, PhD (Co-Chair)

Michael Boss, PhD

Lisa Cimino, RT

Kiran Dhakal, PhD

Bradley Erickson, MD, PhD

Zhaoyang Fan, PhD

Leland Hu, MD

Nancy Obuchowski, PhD

Yuxiang Zhou, PhD, DABR

RSNA

Joe Koudelik

Susan Stanfa

The following topics were discussed:

- DSC-MRI BC leadership: Dr. Shiroishi has accepted the invitation to serve as Co-chair, effective Jan. 10, 2022
- Progress update on the DSC-MRI [white paper draft](#), which can be found in the [Google Drive](#)
- QIBA Process Committee guidance on [vetting checklist requirements](#)
 - This practice will minimize Profile length and improve usability, which will lead to broader adoption
 - To remain in the checklist, requirements must discernably impact the performance of the biomarker as expressed in the Claim
- [Technical Confirmation \(Profile stage 3\) process](#)

Action items

- [White paper](#) assignments
 - Section contributors were reminded to focus on the reproducibility of DSC-MR as a quantitative imaging biomarker; this was not considered a consensus paper
 - Dr. Shiroishi to assess remaining work in clinical sections and provide instruction to Drs. Erickson, Lu and Boxerman
 - Drs. Wu and Zhou to focus on technical aspects of image acquisition and phantom use
 - Assignees to refer to Dave et al. and Chalian, et al. papers located in [Articles folder](#) in DSC Google Drive as templates; staff can be contacted regarding access issues
 - Progress update to occur during next meeting on Feb. 9
- It was recommended that checklist requirements be vetted in parallel with white paper writing to avoid referring to outdated or dropped checklist requirements removed during the vetting process
 - The checklist will be updated both as a result of DSC-MRI BC vetting as well as in response to testing site feedback received during the Technical Confirmation (stage 3) process
 - To feasibility test the Profile for adoption in clinical trials, it was recommended to recruit sites that are naïve to the DSC-MRI Profile

Next DSC-MRI BC Meeting: Wednesday, February 9, 2022, at 11 a.m. CT

RSNA Staff attempt to capture all committee members participating on Zoom meetings. However, if attendees join only by phone, or do not use a recognizable name, identification is not possible. Participants are welcome to contact RSNA staff at giba@rsna.org if their attendance is not reflected in meeting summaries.